National Centre for Pharmacoeconomics. (2013) Delta-9-tetrahydrocannabinol (THC) /Cannabidiol (CBD) (Sativex®). Dublin: National Centre for Pharmacoeconomics.
| Preview | Title | Contact |
|---|---|---|
|
PDF (Summary)
- Published Version
148kB |
For symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
Item Type
Report
Publication Type
Irish-related, Report
Drug Type
Cannabis, Prescription/Over the counter
Intervention Type
Drug therapy
Date
2013
Pages
7 p.
Publisher
National Centre for Pharmacoeconomics
Corporate Creators
National Centre for Pharmacoeconomics
Place of Publication
Dublin
EndNote
Accession Number
HRB (Electronic Only)
Related (external) link
Subjects
B Substances > Cannabis product (Cannabinoids)
B Substances > Cannabis product (Cannabinoids) > Cannabinol / Cannabidiol (CBD oil)
E Concepts in biomedical areas > Medical substance > Prescription drug (medicine / medication)
E Concepts in biomedical areas > Medical substance > Medical / medicinal cannabis
L Social psychology and related concepts > Legal availability or accessibility
VA Geographic area > Europe > Ireland
B Substances > Cannabis product (Cannabinoids) > Cannabinol / Cannabidiol (CBD oil)
E Concepts in biomedical areas > Medical substance > Prescription drug (medicine / medication)
E Concepts in biomedical areas > Medical substance > Medical / medicinal cannabis
L Social psychology and related concepts > Legal availability or accessibility
VA Geographic area > Europe > Ireland
Repository Staff Only: item control page